About Eyenuk, Inc.

Eyenuk was founded by machine learning and image analysis expert Kaushal Solanki (PhD, UCSB).

Eyenuk was founded in December 2010 by Dr. Solanki in his small studio apartment in San Luis Obispo, California, USA.

Harnessing the power of AI to analyze retinal images was the inspiration of Kaushal Solanki, Eyenuk CEO & founder. During his own eye health scare, Solanki faced a four-month wait to see an ophthalmologist for reading and diagnosis of his retinal scans. Knowing his father’s diabetes carried the risk of DR gave Solanki double motivation to develop an algorithm that could quickly and accurately read retinal images for diagnosis and tracking progression of diseases.

Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease.

Eyenuk Inc., is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance.

Yes, Eyenuk is working on a wide portfolio of AI-driven diagnostic products to fulfill its mission. You can read more about our other products here.

About EyeArt®

The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.

The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit. The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects lesions and signs of disease, and returns an easy-to-read report in under 60 seconds.

EyeArt reports a 91.3% sensitivity for referable DR and a 98.5% sensitivity for vision-threatening DR in a large study of over 100,000 consecutive patient visits to over 400 primary care clinics. Read More.

Using EyeArt

The EyeArt System works with multiple color fundus cameras, so providers can choose the camera that works best for their practice.

EyeArt AI Eye Screening is primarily cloud-based with a thin client software that can be installed on most Windows PCs with internet access. No additional software is required.

The EyeArt System provides easy-to-read, actionable reports in under 60 seconds that clearly show a positive or negative screening result and indicate for each eye presence or absence of referable and vision threatening diabetic retinopathy based on clinical practice recommendations of the American Academy of Ophthalmology (AAO).  In addition, outside United States, EyeArt reports also indicate for each eye the level of diabetic retinopathy and presence of markers for diabetic macular edema based on international clinical standards.

The EyeArt System is designed to be easy to use and can be employed by nurses or technicians, eliminating the need for expert human grading or an over-read from an eye care specialist for DR screening.

Please get in touch with us for information on pricing.

Please get in touch with us for reimbursement and coding details.

Using AI in Medicine

The EyeArt AI Eye Screening system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.

No. Using AI to do the initial screening allows timely detection of silently progressing, vision-threatening DR, and allows eye care specialists to focus on the greatest need of sight-saving DR therapy and not on baseline screening.

Eyenuk is extending AI Eye Screening to screen for other potentially blinding eye diseases including Age-related Macular Degeneration (AMD) and Glaucoma.

Eyenuk is also developing AI Predictive Biomarkers™ for risk assessment and surveillance (monitoring progression) for a multitude of diseases including DR, AMD, Glaucoma, Alzheimer’s disease, cardiovascular conditions and stroke.

Validation and Studies of EyeArt